113 related articles for article (PubMed ID: 11892015)
1. Estrogen and progesterone hormone receptor status in breast carcinoma: comparison of immunocytochemistry and immunohistochemistry.
Tafjord S; Bøhler PJ; Risberg B; Torlakovic E
Diagn Cytopathol; 2002 Mar; 26(3):137-41. PubMed ID: 11892015
[TBL] [Abstract][Full Text] [Related]
2. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
[TBL] [Abstract][Full Text] [Related]
3. Proportion of estrogen or progesterone receptor expressing cells in breast cancers and response to endocrine therapy.
Honma N; Horii R; Iwase T; Saji S; Younes M; Ito Y; Akiyama F
Breast; 2014 Dec; 23(6):754-62. PubMed ID: 25176593
[TBL] [Abstract][Full Text] [Related]
4. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
Lew M; Pang JC; Jing X; Fields KL; Roh MH
Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of histopathologic changes and expression of biomarkers in breast carcinoma before and after neoadjuvant chemotherapy].
Zheng S; Zhang BL; Xiao T; Zou SM; Xue LY; Luo W; Guo L; Liu XY; Lü N
Zhonghua Bing Li Xue Za Zhi; 2011 Jul; 40(7):465-70. PubMed ID: 22088373
[TBL] [Abstract][Full Text] [Related]
6. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.
Badve SS; Baehner FL; Gray RP; Childs BH; Maddala T; Liu ML; Rowley SC; Shak S; Perez EA; Shulman LJ; Martino S; Davidson NE; Sledge GW; Goldstein LJ; Sparano JA
J Clin Oncol; 2008 May; 26(15):2473-81. PubMed ID: 18487567
[TBL] [Abstract][Full Text] [Related]
7. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
[TBL] [Abstract][Full Text] [Related]
8. [Immunohistochemical investigation of steroid hormones (ER, PR) in breast cancer].
Mchedlishvili MIu; Gabunia UA; Makharoblidze ER; Burnadze KT; Piradashvili DZ
Georgian Med News; 2005 Feb; (119):65-7. PubMed ID: 15834186
[TBL] [Abstract][Full Text] [Related]
9. Correlation between hormone receptor status and age, and its prognostic implications in breast cancer patients in Bahrain.
AlZaman AS; Mughal SA; AlZaman YS; AlZaman ES
Saudi Med J; 2016 Jan; 37(1):37-42. PubMed ID: 26739972
[TBL] [Abstract][Full Text] [Related]
10. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.
Fournier A; Fabre A; Mesrine S; Boutron-Ruault MC; Berrino F; Clavel-Chapelon F
J Clin Oncol; 2008 Mar; 26(8):1260-8. PubMed ID: 18323549
[TBL] [Abstract][Full Text] [Related]
11. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
12. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.
Tong LC; Nelson N; Tsourigiannis J; Mulligan AM
Am J Surg Pathol; 2011 Apr; 35(4):545-52. PubMed ID: 21358301
[TBL] [Abstract][Full Text] [Related]
13. Do clinical features and survival of single hormone receptor positive breast cancers differ from double hormone receptor positive breast cancers?
Ng CH; Pathy NB; Taib NA; Ho GF; Mun KS; Rhodes A; Looi LM; Yip CH
Asian Pac J Cancer Prev; 2014; 15(18):7959-64. PubMed ID: 25292095
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
Khabaz MN
Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
16. The estrogen receptor negative-progesterone receptor positive breast carcinoma is a biological entity and not a technical artifact.
Ng CH; Pathy NB; Taib NA; Mun KS; Rhodes A; Yip CH
Asian Pac J Cancer Prev; 2012; 13(4):1111-3. PubMed ID: 22799290
[TBL] [Abstract][Full Text] [Related]
17. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
18. Cyclin D1 overexpression associates with favourable prognostic factors in invasive breast carcinoma.
El-Hafez AA; El Aaty Shawky A; Hasan B
Cancer Biomark; 2012; 12(4):149-54. PubMed ID: 23568005
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
[TBL] [Abstract][Full Text] [Related]
20. Comparison of immunohistochemistry assays and real-time reverse transcription-polymerase chain reaction for analyzing hormone receptor status in human breast carcinoma.
Oda M; Arihiro K; Kataoka T; Osaki A; Asahara T; Ohdan H
Pathol Int; 2010 Apr; 60(4):305-15. PubMed ID: 20403033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
